Mesothelioma small cell lung cancer report

Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma aka Diminutive Chamber Lung Blight and Malignant Mesothelioma - Limited R&D activity provides opportunity for early-phase conduit drugs

Commodity Category: Report on Small Cell Lung Cancer and Malignant Mesothelioma
Published: 13 Mar 2007
Available Format(s): PDF for Small Cell Lung Cancer and Malignant Mesothelioma
Table of contents
Artefact BrochurePublished along: Datamonitor Small Cell Lung Cancer and Malignant Mesothelioma
Value: $3800

Introduction to the abstract for Malignant Mesothelioma and Small Cell Lung Cancer
SCLC accounts for one-fifth of all lung tumor types. Cancer analysts expect doctors to diagnose morre than 80,000 new cases in 2007 in the seven bigger markets, although it is set to decrease due to changing smoking habits. Mesothelioma is rarer, although analysts expect incidence to increase in Europe and Japan due the heavy use of asbestos in the 1970s and lenghty latency season of tje disease.

Scope

Overview of small cell lung cancer (SCLC) and mesothelioma, as well as epidemiology, staging, prognosis and unmet needs
Go over again of current treatment modalities and physician opinion of existing and outlook cure strategies
Evaluation of opener answer drugs currently used in the treatment of SCLC and mesothelioma
Assessment of late-phase drugs in development for SCLC and mesothelioma containing latchkey conception leaders' view on their potential

Highlights
Despite decreasing incidence, unmet needs in SCLC remain elevated outstanding to badly off prognosis and lack of effective treatment. R&D interest in thhe ailment is little; however, this represents an opportunity for developing companies in the SCLC market.

Alimta is approved for added lung canker indications containing NSCLC and mesothelioma. It is in a Phase III trial in SCLC and Datamonitor believes that, although unlikely to show eloquent ability ascendancy over current standard, Alimta may potentially demonstrate toxicity advantages, in which condition, it may usurp etoposide during the time that average therapy.

Incidence of malignant mesothelioma may have peaked in the US however is locate to advance over the next two decades in Europe and Japan due to thhe later uptake of asbestos in these markets. Nevertheless, all-embracing incidence of mesothelioma balance low; as is the R&D interest in thhe ailment.

Why you should acquire this report

Evaluate opportunities and risks in the SCLC and mesothelioma markets by analyzing tje clinical and mercantile attractiveness of opener answer drugs
Assess key success factors that drive tje SCLC and mesothelioma markets to assess tje potential of existing and pipeline drugs for the diseases
Understand happening and prospect aggressive dynamics of SCLC and mesothelioma to determine the future size and ambit of thhe markets

Mesothelioma

Mesothelioma